Efficacy of chemotherapy for advanced non-small cell lung cancer with idiopathic pulmonary fibrosis

Naohiro Watanabe, Hiroyuki Taniguchi, Yasuhiro Kondoh, Tomoki Kimura, Kensuke Kataoka, Osamu Nishiyama, Masashi Kondo, Yoshinori Hasegawa

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Background: Idiopathic pulmonary fibrosis (IPF) is the most common type of idiopathic interstitial pneumonia and is associated with an independent increased risk of lung carcinogenesis. The benefit of chemotherapy for lung cancer in cases of IPF remains unknown. Objectives: This study was conducted to elucidate the efficacy of chemotherapy for advanced non-small cell lung cancer (NSCLC) in patients with IPF. Methods: Advanced (i.e. stage IIIB and IV) NSCLC patients with IPF who received systemic chemotherapy were studied. Response rate, toxicity, overall survival and progression-free survival were investigated. Results: Between January 2000 and December 2009, 21 patients were enrolled in this study and treated with chemotherapy. The overall response rate with the 1st regimen was 42.9%. The median overall survival was 11.4 months, the 1-year survival rate was 28.6% and the median PFS was 5.4 months. Conclusions: This study showed that advanced NSCLC patients with IPF may benefit from chemotherapy; well-controlled studies are still needed to clarify the efficacy.

Original languageEnglish
Pages (from-to)326-331
Number of pages6
JournalRespiration
Volume85
Issue number4
DOIs
Publication statusPublished - 01-01-2013

Fingerprint

Idiopathic Pulmonary Fibrosis
Non-Small Cell Lung Carcinoma
Drug Therapy
Idiopathic Interstitial Pneumonias
Survival
Disease-Free Survival
Lung Neoplasms
Carcinogenesis
Survival Rate
Lung

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

Watanabe, N., Taniguchi, H., Kondoh, Y., Kimura, T., Kataoka, K., Nishiyama, O., ... Hasegawa, Y. (2013). Efficacy of chemotherapy for advanced non-small cell lung cancer with idiopathic pulmonary fibrosis. Respiration, 85(4), 326-331. https://doi.org/10.1159/000342046
Watanabe, Naohiro ; Taniguchi, Hiroyuki ; Kondoh, Yasuhiro ; Kimura, Tomoki ; Kataoka, Kensuke ; Nishiyama, Osamu ; Kondo, Masashi ; Hasegawa, Yoshinori. / Efficacy of chemotherapy for advanced non-small cell lung cancer with idiopathic pulmonary fibrosis. In: Respiration. 2013 ; Vol. 85, No. 4. pp. 326-331.
@article{61fe2118700e4087a99ba629e7286434,
title = "Efficacy of chemotherapy for advanced non-small cell lung cancer with idiopathic pulmonary fibrosis",
abstract = "Background: Idiopathic pulmonary fibrosis (IPF) is the most common type of idiopathic interstitial pneumonia and is associated with an independent increased risk of lung carcinogenesis. The benefit of chemotherapy for lung cancer in cases of IPF remains unknown. Objectives: This study was conducted to elucidate the efficacy of chemotherapy for advanced non-small cell lung cancer (NSCLC) in patients with IPF. Methods: Advanced (i.e. stage IIIB and IV) NSCLC patients with IPF who received systemic chemotherapy were studied. Response rate, toxicity, overall survival and progression-free survival were investigated. Results: Between January 2000 and December 2009, 21 patients were enrolled in this study and treated with chemotherapy. The overall response rate with the 1st regimen was 42.9{\%}. The median overall survival was 11.4 months, the 1-year survival rate was 28.6{\%} and the median PFS was 5.4 months. Conclusions: This study showed that advanced NSCLC patients with IPF may benefit from chemotherapy; well-controlled studies are still needed to clarify the efficacy.",
author = "Naohiro Watanabe and Hiroyuki Taniguchi and Yasuhiro Kondoh and Tomoki Kimura and Kensuke Kataoka and Osamu Nishiyama and Masashi Kondo and Yoshinori Hasegawa",
year = "2013",
month = "1",
day = "1",
doi = "10.1159/000342046",
language = "English",
volume = "85",
pages = "326--331",
journal = "Respiration; international review of thoracic diseases",
issn = "0025-7931",
publisher = "S. Karger AG",
number = "4",

}

Watanabe, N, Taniguchi, H, Kondoh, Y, Kimura, T, Kataoka, K, Nishiyama, O, Kondo, M & Hasegawa, Y 2013, 'Efficacy of chemotherapy for advanced non-small cell lung cancer with idiopathic pulmonary fibrosis', Respiration, vol. 85, no. 4, pp. 326-331. https://doi.org/10.1159/000342046

Efficacy of chemotherapy for advanced non-small cell lung cancer with idiopathic pulmonary fibrosis. / Watanabe, Naohiro; Taniguchi, Hiroyuki; Kondoh, Yasuhiro; Kimura, Tomoki; Kataoka, Kensuke; Nishiyama, Osamu; Kondo, Masashi; Hasegawa, Yoshinori.

In: Respiration, Vol. 85, No. 4, 01.01.2013, p. 326-331.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy of chemotherapy for advanced non-small cell lung cancer with idiopathic pulmonary fibrosis

AU - Watanabe, Naohiro

AU - Taniguchi, Hiroyuki

AU - Kondoh, Yasuhiro

AU - Kimura, Tomoki

AU - Kataoka, Kensuke

AU - Nishiyama, Osamu

AU - Kondo, Masashi

AU - Hasegawa, Yoshinori

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Background: Idiopathic pulmonary fibrosis (IPF) is the most common type of idiopathic interstitial pneumonia and is associated with an independent increased risk of lung carcinogenesis. The benefit of chemotherapy for lung cancer in cases of IPF remains unknown. Objectives: This study was conducted to elucidate the efficacy of chemotherapy for advanced non-small cell lung cancer (NSCLC) in patients with IPF. Methods: Advanced (i.e. stage IIIB and IV) NSCLC patients with IPF who received systemic chemotherapy were studied. Response rate, toxicity, overall survival and progression-free survival were investigated. Results: Between January 2000 and December 2009, 21 patients were enrolled in this study and treated with chemotherapy. The overall response rate with the 1st regimen was 42.9%. The median overall survival was 11.4 months, the 1-year survival rate was 28.6% and the median PFS was 5.4 months. Conclusions: This study showed that advanced NSCLC patients with IPF may benefit from chemotherapy; well-controlled studies are still needed to clarify the efficacy.

AB - Background: Idiopathic pulmonary fibrosis (IPF) is the most common type of idiopathic interstitial pneumonia and is associated with an independent increased risk of lung carcinogenesis. The benefit of chemotherapy for lung cancer in cases of IPF remains unknown. Objectives: This study was conducted to elucidate the efficacy of chemotherapy for advanced non-small cell lung cancer (NSCLC) in patients with IPF. Methods: Advanced (i.e. stage IIIB and IV) NSCLC patients with IPF who received systemic chemotherapy were studied. Response rate, toxicity, overall survival and progression-free survival were investigated. Results: Between January 2000 and December 2009, 21 patients were enrolled in this study and treated with chemotherapy. The overall response rate with the 1st regimen was 42.9%. The median overall survival was 11.4 months, the 1-year survival rate was 28.6% and the median PFS was 5.4 months. Conclusions: This study showed that advanced NSCLC patients with IPF may benefit from chemotherapy; well-controlled studies are still needed to clarify the efficacy.

UR - http://www.scopus.com/inward/record.url?scp=84876140926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876140926&partnerID=8YFLogxK

U2 - 10.1159/000342046

DO - 10.1159/000342046

M3 - Article

VL - 85

SP - 326

EP - 331

JO - Respiration; international review of thoracic diseases

JF - Respiration; international review of thoracic diseases

SN - 0025-7931

IS - 4

ER -

Watanabe N, Taniguchi H, Kondoh Y, Kimura T, Kataoka K, Nishiyama O et al. Efficacy of chemotherapy for advanced non-small cell lung cancer with idiopathic pulmonary fibrosis. Respiration. 2013 Jan 1;85(4):326-331. https://doi.org/10.1159/000342046